Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06HBQ
|
|||
| Former ID |
DAP000924
|
|||
| Drug Name |
Gliquidone
|
|||
| Synonyms |
Beglynor; Beglynora; Glikvidon; Gliquidona; Gliquidonum; Glurenorm; Glycvidon; ARDF 26; ARDF 26 SE; AR-DF 26; Gliquidona [INN-Spanish]; Gliquidone (INN); Gliquidone [BAN:INN]; Gliquidonum [INN-Latin]; Glurenorm (TN); N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide; 1-Cyclohexyl-3-((p-(2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolyl)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-(p-beta-(4,4-dimethyl-2-methoxy-1,3-(2H,4H)-isoquinolinedione-2-yl)phenethyl)sulfonylurea; 1-cyclohexyl-3-(p-beta-(4,4-dimethyl-2-methoxy-1,3-(2H,4H)-isoquinolinedione-2-yl)phenethyl)sulfonylurea; 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxoisoquinolin-2-yl)ethyl]phenyl]sulfonylurea
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-9: 253.5, 588.1] | Approved | [1] | |
| Therapeutic Class |
Hypoglycemic Agents
|
|||
| Company |
Boehriger Ingelheim
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H33N3O6S
|
|||
| Canonical SMILES |
CC1(C2=C(C=C(C=C2)OC)C(=O)N(C1=O)CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C
|
|||
| InChI |
1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)
|
|||
| InChIKey |
LLJFMFZYVVLQKT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 33342-05-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7449309, 7849488, 7979418, 10224909, 11112731, 11467019, 11468139, 11486708, 14860897, 44422540, 46508425, 47381693, 47381694, 47604985, 47901629, 48351264, 48416055, 49699236, 49832468, 49881412, 50060569, 50085433, 50124024, 50796154, 56463591, 57334969, 81041002, 81065941, 81092899, 85787540, 87560715, 92125987, 92717029, 103481945, 103914607, 104405238, 105585086, 121363658, 124882576, 124882577, 125204729, 125348208, 126622557, 126654118, 126739661, 128505786, 131310850, 134338200, 135049036, 137005778
|
|||
| ChEBI ID |
CHEBI:93416
|
|||
| SuperDrug ATC ID |
A10BB08
|
|||
| SuperDrug CAS ID |
cas=033342051
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Clostridioides difficile
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridioides difficile was decreased by Gliquidone (adjusted p-values: 6.07E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Inward rectifier potassium channel Kir1.2 (KCNJ10) | Target Info | Binder | [3] |
| KEGG Pathway | Gastric acid secretion | |||
| Reactome | Activation of G protein gated Potassium channels | |||
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | ||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| Potassium Channels | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drug information of Gliquidone, 2008. eduDrugs. | |||
| REF 2 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 3 | Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.